Abstract

Purine nucleoside phosphorylase (PNP) is an important enzyme in the purine degradation and salvage pathway. PNP deficiency results in marked T lineage lymphopenia and severe immunodeficiency. Additionally, PNP-deficient patients and mice suffer from diverse non-infectious neurological abnormalities of unknown etiology. To further investigate the cause for these neurologic abnormalities, induced pluripotent stem cells (iPSC) from two PNP-deficient patients were differentiated into neurons. The iPSC-derived PNP-deficient neurons had significantly reduced soma and nuclei volumes. The PNP-deficient neurons demonstrated increased spontaneous and staurosporine-induced apoptosis, measured by cleaved caspase-3 expression, together with decreased mitochondrial membrane potential and increased cleaved caspase-9 expression, indicative of enhanced intrinsic apoptosis. Greater expression of tumor protein p53 was also observed in these neurons, and inhibition of p53 using pifithrin-α prevented the apoptosis. Importantly, treatment of the iPSC-derived PNP-deficient neurons with exogenous PNP enzyme alleviated the apoptosis. Inhibition of ribonucleotide reductase (RNR) in iPSC derived from PNP-proficient neurons with hydroxyurea or with nicotinamide and trichostatin A increased the intrinsic neuronal apoptosis, implicating RNR dysfunction as the potential mechanism for the damage caused by PNP deficiency. The findings presented here establish a potential mechanism for the neurological defects observed in PNP-deficient patients and reinforce the critical role that PNP has for neuronal viability.

Details

Title
Purine nucleoside phosphorylase deficiency induces p53-mediated intrinsic apoptosis in human induced pluripotent stem cell-derived neurons
Author
Tsui, Michael 1 ; Biro, Jeremy 2 ; Chan, Jonathan 2 ; Min, Weixian 2 ; Dobbs, Kerry 3 ; Notarangelo, Luigi D. 3 ; Grunebaum, Eyal 4 

 Hospital for Sick Children, Developmental and Stem Cell Biology Program, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); The University to Toronto, The Institute of Medical Sciences, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
 Hospital for Sick Children, Developmental and Stem Cell Biology Program, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646) 
 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, Bethesda, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667) 
 Hospital for Sick Children, Developmental and Stem Cell Biology Program, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); The University to Toronto, The Institute of Medical Sciences, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); The Hospital for Sick Children, Division of Immunology and Allergy, Department of Pediatrics, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2671803109
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.